Effects of Eprosartan Versus Enalapril in Hypertensive Patients on the Renin-Angiotensin-Aldosterone System and Safety Parameters: Results from a 26-Week, Double-blind, Multicentre Study

References

• Kang P. M., Landau A. J., Eberhardt R. T., Frishman W. H. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am. Heart J. 1994; 127: 1388–14011. Kang P. M., Landau A. J., Eberhardt R. T., Frishman W. H. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am. Heart J. 1994; 127: 1388–1401
   PubMed Web of Science ®Google Scholar
• Anionics T. F. T., MacGregor G. A. Angiotensin converting enzyme inhibitors in hypertension: potential problems. J. Hypertens. 1995; 13: S11–S16, Suppl 32. Anionics T. F. T., MacGregor G. A. Angiotensin converting enzyme inhibitors in hypertension: potential problems. J. Hypertens. 1995; 13: S11–S16, Suppl 3
   Web of Science ®Google Scholar
• Alderman C. P. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. 1996; 30: 55–613. Alderman C. P. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann. Pharmacother. 1996; 30: 55–61
   PubMed Web of Science ®Google Scholar
• Israili Z. H., Hall W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med. 1992; 117: 234–3424. Israili Z. H., Hall W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann. Intern. Med. 1992; 117: 234–342
   PubMed Web of Science ®Google Scholar
• Semple P. F. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens. 1995; 13: S17–S21, Suppl 35. Semple P. F. Putative mechanisms of cough after treatment with angiotensin converting enzyme inhibitors. J. Hypertens. 1995; 13: S17–S21, Suppl 3
   Web of Science ®Google Scholar
• Ohlstein E. H., Brooks D. P., Feuerstein G. Z., Ruffolo R. R., Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55: 244–2516. Ohlstein E. H., Brooks D. P., Feuerstein G. Z., Ruffolo R. R., Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology 1997; 55: 244–251
   PubMed Web of Science ®Google Scholar
• Edwards R. M., Aiyar N., Ohlstein E. H., et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J. Pharmacol. Exp. Ther. 1992; 260: 175–1817. Edwards R. M., Aiyar N., Ohlstein E. H., et al. Pharmacological characterization of the nonpeptide angiotensin II receptor antagonist, SK&F 108566. J. Pharmacol. Exp. Ther. 1992; 260: 175–181
   PubMed Web of Science ®Google Scholar
• Elliott W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J. Hum. Hypertens. 1999, in press8. Elliott W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J. Hum. Hypertens. 1999, in press
   PubMedGoogle Scholar
• Sealey J. E. Plasma renin activity and plasma prorenin assays. Clin. Chem. 1991; 37: 1811–18199. Sealey J. E. Plasma renin activity and plasma prorenin assays. Clin. Chem. 1991; 37: 1811–1819
   PubMed Web of Science ®Google Scholar
• Bragat A. C., Blumenfeld J., Sealey J. E. Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J. Hypertens. 1997; 15: 459–46510. Bragat A. C., Blumenfeld J., Sealey J. E. Effect of high-performance liquid chromatography on plasma angiotensin II measurements in treated and untreated normotensive and hypertensive patients. J. Hypertens. 1997; 15: 459–465
   PubMed Web of Science ®Google Scholar
• Fuller R. W., Choudry N. E. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. BMJ 1987; 295: 1025–102611. Fuller R. W., Choudry N. E. Increased cough reflex associated with angiotensin converting enzyme inhibitor cough. BMJ 1987; 295: 1025–1026
   PubMed Web of Science ®Google Scholar
• McEwan J. R., Choudry N., Street R., Fuller R. W. Change in cough reflex after treatment with enalapril and ramipril. BMJ 1989; 299: 13–1612. McEwan J. R., Choudry N., Street R., Fuller R. W. Change in cough reflex after treatment with enalapril and ramipril. BMJ 1989; 299: 13–16
   PubMed Web of Science ®Google Scholar
• Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992; 42: 1020–102913. Gavras I. Bradykinin-mediated effects of ACE inhibition. Kidney Int. 1992; 42: 1020–1029
   PubMed Web of Science ®Google Scholar
• Fuller R. W., Dixon C. M., Cuss F. M., Barnes P. J. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am. Rev. Respir. Dis. 1987; 135: 176–18014. Fuller R. W., Dixon C. M., Cuss F. M., Barnes P. J. Bradykinin-induced bronchoconstriction in humans. Mode of action. Am. Rev. Respir. Dis. 1987; 135: 176–180
   PubMed Web of Science ®Google Scholar
• Coleridge H. M., Coleridge J. C., Ginzel K. H., et al. Stimulation of irritant receptors and afferent C-fibers in the lungs by prostaglandins. Nature 1976; 264: 451–45315. Coleridge H. M., Coleridge J. C., Ginzel K. H., et al. Stimulation of irritant receptors and afferent C-fibers in the lungs by prostaglandins. Nature 1976; 264: 451–453
   PubMed Web of Science ®Google Scholar
• Lacourciere Y., Brunner H. R., Irwin R., et al. Effect of modulators of the rennin-angiotensin aldosterone system on cough. J. Hypertens. 1994; 12: 1387–139316. Lacourciere Y., Brunner H. R., Irwin R., et al. Effect of modulators of the rennin-angiotensin aldosterone system on cough. J. Hypertens. 1994; 12: 1387–1393
   PubMed Web of Science ®Google Scholar
• Waeber B., Brunner H. R., Brunner D. B., et al. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980; 2: 236–24217. Waeber B., Brunner H. R., Brunner D. B., et al. Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril. Hypertension 1980; 2: 236–242
   PubMed Web of Science ®Google Scholar
• Mackay J. H., Arcuri K. E., Goldberg A. I., Snapinn S. M., Sweet C. S. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch. Intern. Med. 1996; 156: 278–28518. Mackay J. H., Arcuri K. E., Goldberg A. I., Snapinn S. M., Sweet C. S. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components. Arch. Intern. Med. 1996; 156: 278–285
   PubMed Web of Science ®Google Scholar
• Ruilope L. M., Simpson R. L., Toh J., et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood. Press. 1996; 5: 32–4019. Ruilope L. M., Simpson R. L., Toh J., et al. Controlled trial of losartan given concomitantly with different doses of hydrochlorothiazide in hypertensive patients. Blood. Press. 1996; 5: 32–40
   PubMedGoogle Scholar
• Gavras H., Liang C., Brunner H. R. Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. Circ. Res. 1978; 43: 59–63, Suppl 120. Gavras H., Liang C., Brunner H. R. Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. Circ. Res. 1978; 43: 59–63, Suppl 1
   Google Scholar
• Wang Y-X., Gavras I., Wierzba T., Gavras H. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin-II receptor antagonist, and an angiotensin-converting enzyme inhibitor. J. Lab. Clin. Med. 1992; 119: 267–27221. Wang Y-X., Gavras I., Wierzba T., Gavras H. Comparison of systemic and regional hemodynamic effects of a diuretic, an angiotensin-II receptor antagonist, and an angiotensin-converting enzyme inhibitor. J. Lab. Clin. Med. 1992; 119: 267–272
   PubMedGoogle Scholar
• Pitt B., Segal R., Martinez F. A., et al. on behalf of the ELITE investigators Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–75122. Pitt B., Segal R., Martinez F. A., et al. on behalf of the ELITE investigators Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747–751
   PubMed Web of Science ®Google Scholar